TRBJ2-6: A Protein Regulating B Cell Development (G28623)

Target Name: TRBJ2-6

NCBI ID: G28623

TRBJ2-6

Other Name(s): TCRBJ2S6 | T cell receptor beta joining 2-6 | TRBJ26

TRBJ2-6: A Protein Regulating B Cell Development

TRBJ2-6 (Tumor-associated B cell javax protein 2-6) is a protein that is expressed in a variety of tissues, including the brain, spleen, and lymphoid organs. It is a member of the B celljavax gene family, which is involved in the development and regulation of B cells, which are a type of white blood cell that play a critical role in the immune system.

TRBJ2-6 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, spleen, and lymphoid organs. It is a member of the B celljavax gene family, which is involved in the development and regulation of B cells. B cells are a type of white blood cell that play a critical role in the immune system. They are responsible for producing antibodies, which are proteins that help to neutralize or destroy pathogens that have entered the body.

One of the functions of TRBJ2-6 is to regulate the development and maturation of B cells. B cells are produced in the bone marrow, and they mature and become functional in the spleen and lymphoid organs. During this process, TRBJ2-6 plays a role in the regulation of the number and type of B cells that are produced.

Another function of TRBJ2-6 is to modulate the activity of B cells. B cells are able to recognize and respond to specific antigens, and TRBJ2-6 plays a role in regulating the strength and diversity of the responses of B cells to these antigens. This helps to ensure that the immune system is able to respond effectively to a wide range of threats.

In addition to its role in regulating B cell development and maturation, TRBJ2-6 may also be a drug target or biomarker. For example, some studies have suggested that TRBJ2-6 may be a potential target for new cancer therapies because it is highly expressed in a variety of cancer types. Additionally, high levels of TRBJ2-6 have been observed in a variety of diseases, including autoimmune diseases and certain types of cancer. This suggests that it may be a useful indicator of the severity or progression of these conditions.

Overall, TRBJ2-6 is a protein that is involved in the regulation of B cell development and maturation. It is expressed in a variety of tissues and may be a potential drug target or biomarker for a variety of diseases. Further research is needed to fully understand the role of TRBJ2-6 in the immune system and its potential as a therapeutic target.

Protein Name: T Cell Receptor Beta Joining 2-6

Functions: J region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBJ2-6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBJ2-6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets